Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy

BACKGROUND: Few treatment options are available for brain metastases (BMs) in EGFR-mutant non-small cell lung cancer (NSCLC) that progress with prior EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy. This study aimed to evaluate the efficacy of immune checkpoint inhibitor (ICI) therapy in these pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shujie, Ren, Fei, Meng, Xiangjiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552846/
https://www.ncbi.nlm.nih.gov/pubmed/36238280
http://dx.doi.org/10.3389/fimmu.2022.955944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552846/
https://www.ncbi.nlm.nih.gov/pubmed/36238280
http://dx.doi.org/10.3389/fimmu.2022.955944

Ejemplares similares